156 related articles for article (PubMed ID: 31630405)
1. Quantitative Proteomics and Mechanistic Modeling of Transporter-Mediated Disposition in Nonalcoholic Fatty Liver Disease.
Vildhede A; Kimoto E; Pelis RM; Rodrigues AD; Varma MVS
Clin Pharmacol Ther; 2020 May; 107(5):1128-1137. PubMed ID: 31630405
[TBL] [Abstract][Full Text] [Related]
2. Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics.
Wang L; Collins C; Kelly EJ; Chu X; Ray AS; Salphati L; Xiao G; Lee C; Lai Y; Liao M; Mathias A; Evers R; Humphreys W; Hop CE; Kumer SC; Unadkat JD
Drug Metab Dispos; 2016 Nov; 44(11):1752-1758. PubMed ID: 27543206
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Effects of Different Models of Nonalcoholic Fatty Liver Disease in Transgenic Humanized OATP1B Mice.
Bechtold BJ; Lynch KD; Oyanna VO; Call MR; White LA; Graf TN; Oberlies NH; Clarke JD
Drug Metab Dispos; 2024 Apr; 52(5):355-367. PubMed ID: 38485280
[TBL] [Abstract][Full Text] [Related]
4. Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3-Glucuronide in Nonalcoholic Steatohepatitis.
Sjöstedt N; Neuhoff S; Brouwer KLR
Clin Pharmacol Ther; 2021 Mar; 109(3):676-687. PubMed ID: 32897538
[TBL] [Abstract][Full Text] [Related]
5. Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.
Canet MJ; Merrell MD; Hardwick RN; Bataille AM; Campion SN; Ferreira DW; Xanthakos SA; Manautou JE; A-Kader HH; Erickson RP; Cherrington NJ
Drug Metab Dispos; 2015 Jun; 43(6):829-35. PubMed ID: 25788542
[TBL] [Abstract][Full Text] [Related]
6. Major glucuronide metabolites of testosterone are primarily transported by MRP2 and MRP3 in human liver, intestine and kidney.
Li CY; Basit A; Gupta A; Gáborik Z; Kis E; Prasad B
J Steroid Biochem Mol Biol; 2019 Jul; 191():105350. PubMed ID: 30959153
[TBL] [Abstract][Full Text] [Related]
7. Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III.
Chatterjee S; Mukherjee S; Sankara Sivaprasad LVJ; Naik T; Gautam SS; Murali BV; Hadambar AA; Gunti GR; Kuchibhotla V; Deyati A; Basavanthappa S; Ramarao M; Mariappan TT; Zinker BA; Zhang Y; Sinz M; Shen H
J Pharmacol Exp Ther; 2021 Jan; 376(1):29-39. PubMed ID: 33127749
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.
Pierre V; Johnston CK; Ferslew BC; Brouwer K; Gonzalez D
CPT Pharmacometrics Syst Pharmacol; 2017 May; 6(5):331-339. PubMed ID: 28417561
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic (PBPK) Model Predictions of Disease Mediated Changes in Drug Disposition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD).
Adiwidjaja J; Spires J; Brouwer KLR
Pharm Res; 2024 Mar; 41(3):441-462. PubMed ID: 38351228
[TBL] [Abstract][Full Text] [Related]
10. Protein Abundance of Clinically Relevant Drug Transporters in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens.
Drozdzik M; Busch D; Lapczuk J; Müller J; Ostrowski M; Kurzawski M; Oswald S
Clin Pharmacol Ther; 2019 May; 105(5):1204-1212. PubMed ID: 30447067
[TBL] [Abstract][Full Text] [Related]
11. Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity.
Jilek JL; Frost KL; Jacobus KA; He W; Toth EL; Goedken M; Cherrington NJ
Acta Pharm Sin B; 2021 Dec; 11(12):3869-3878. PubMed ID: 35024313
[TBL] [Abstract][Full Text] [Related]
12. Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.
Clarke JD; Novak P; Lake AD; Hardwick RN; Cherrington NJ
Liver Int; 2017 Jul; 37(7):1074-1081. PubMed ID: 28097795
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.
Dzierlenga AL; Clarke JD; Hargraves TL; Ainslie GR; Vanderah TW; Paine MF; Cherrington NJ
J Pharmacol Exp Ther; 2015 Mar; 352(3):462-70. PubMed ID: 25512370
[TBL] [Abstract][Full Text] [Related]
14. Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics.
Wang L; Prasad B; Salphati L; Chu X; Gupta A; Hop CE; Evers R; Unadkat JD
Drug Metab Dispos; 2015 Mar; 43(3):367-74. PubMed ID: 25534768
[TBL] [Abstract][Full Text] [Related]
15. Successful Prediction of In Vivo Hepatobiliary Clearances and Hepatic Concentrations of Rosuvastatin Using Sandwich-Cultured Rat Hepatocytes, Transporter-Expressing Cell Lines, and Quantitative Proteomics.
Ishida K; Ullah M; Tóth B; Juhasz V; Unadkat JD
Drug Metab Dispos; 2018 Jan; 46(1):66-74. PubMed ID: 29084782
[TBL] [Abstract][Full Text] [Related]
16. Endogenous Coproporphyrin I and III are Altered in Multidrug Resistance-Associated Protein 2-Deficient (TR
Bezençon J; Saran C; Hussner J; Beaudoin JJ; Zhang Y; Shen H; Fallon JK; Smith PC; Meyer Zu Schwabedissen HE; Brouwer KLR
J Pharm Sci; 2021 Jan; 110(1):404-411. PubMed ID: 33058892
[TBL] [Abstract][Full Text] [Related]
17. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease.
Lickteig AJ; Fisher CD; Augustine LM; Aleksunes LM; Besselsen DG; Slitt AL; Manautou JE; Cherrington NJ
Drug Metab Dispos; 2007 Oct; 35(10):1970-8. PubMed ID: 17640958
[TBL] [Abstract][Full Text] [Related]
18. Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate.
Ali I; Slizgi JR; Kaullen JD; Ivanovic M; Niemi M; Stewart PW; Barritt AS; Brouwer KLR
Clin Pharmacol Ther; 2017 Dec; ():. PubMed ID: 29271075
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
Jamwal R; de la Monte SM; Ogasawara K; Adusumalli S; Barlock BB; Akhlaghi F
Mol Pharm; 2018 Jul; 15(7):2621-2632. PubMed ID: 29792708
[TBL] [Abstract][Full Text] [Related]
20. Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.
Fallon JK; Smith PC; Xia CQ; Kim MS
Pharm Res; 2016 Sep; 33(9):2280-8. PubMed ID: 27356525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
